qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:83f89dfb7196c686f7756d00 | QAG:89a7c61ff4d42ee01899dd2d | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "They further demonstrated that the combined MEK and ERBB inhibition using the MEK inhibitor selumetinib and the pan-ERBB inhibitor neratinib of human organoid orthotopic xenografts led to tumor regression in short-term intervention studies"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d49ad0a9168839cae8cc98fb","quotes":["They further demonstrated that the combined MEK and ERBB inhibition using th... | [
"CLM:d49ad0a9168839cae8cc98fb",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC10046065"
] | [
"SPAN:cc826e715aa19ef98575f020",
"SPAN:f69873176eba56581e87753d"
] | [] | [] | {"qa_id":"QA:83f89dfb7196c686f7756d00","qa_group_id":"QAG:89a7c61ff4d42ee01899dd2d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"They further demonstrated that the combined MEK and ERBB inhibitio... |
QA:852a71b264adf767fa73ccb2 | QAG:de43afd3f611c9c7cb88219f | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Although the stroma plays a role in chemotherapy resistance, it was also shown that elimination of stromal cells led to tumor progression towards a more aggressive phenotype, concluding that the involvement of stroma in PDAC is highly complex and needs to be better und... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:48e5650df2f3938f21a985cb","quotes":["Although the stroma plays a role in chemotherapy resistance, it was also sho... | [
"CLM:48e5650df2f3938f21a985cb",
"CLM:065ed27ad3615b0a901fd1b8"
] | [
"PMCID:PMC9867742"
] | [
"SPAN:d2e9adc14f008375a9e4ad05"
] | [] | [] | {"qa_id":"QA:852a71b264adf767fa73ccb2","qa_group_id":"QAG:de43afd3f611c9c7cb88219f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Although the stroma plays a role in chemotherapy resistance, it wa... |
QA:85a32a8d27e2ab320538b275 | QAG:753799306207cba85555a084 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "(a) PDAC organoids received a serial dilution of gemcitabine (3 nM to 1,000 nM) and imaged over 72 hours"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bbf3505ab875905880781666","quotes":["10.1371/journal.pcbi.1010584.g003 Fig 3 OrganoID fa... | [
"CLM:bbf3505ab875905880781666",
"CLM:0318813e4f6821e1817a7015",
"CLM:1d034a217cdc8e6c24a4fd7c"
] | [
"PMCID:PMC9645660",
"PMCID:PMC10060271"
] | [
"SPAN:92cfc3c4fcb5ae3715991857",
"SPAN:b7509a08900075a0a4ce229b"
] | [
"ASC2:0b8efb3c4b5fe680f32dc5ec"
] | [
"HYP:DCH:a16fedbe0cbffc9af91bc4f4"
] | {"qa_id":"QA:85a32a8d27e2ab320538b275","qa_group_id":"QAG:753799306207cba85555a084","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"(a) PDAC organoids received a serial dilution of gemcitabine (3 nM... |
QA:86c21978e5b3f2e2679c015e | QAG:f1a2e2d8141a6b874640278a | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7757566? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7757566","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7757566"
] | [] | [] | [] | {"qa_id":"QA:86c21978e5b3f2e2679c015e","qa_group_id":"QAG:f1a2e2d8141a6b874640278a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7757566... |
QA:88b11e786f13dbd664b71e62 | QAG:96bbc9bc423d140a6689b89c | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Our observations suggest that basal tumors may exhibit broadly decreased sensitivity to chemotherapy and highlight the need for new strategies to target this transcriptional subtype of PDAC"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f559415d22eb4d26ac54d3f1","quotes":["Our observations suggest that basal tumors may exhibit broadly decreased sen... | [
"CLM:f559415d22eb4d26ac54d3f1",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC8822455"
] | [
"SPAN:f9bb5d0a08e69102251f477b"
] | [] | [] | {"qa_id":"QA:88b11e786f13dbd664b71e62","qa_group_id":"QAG:96bbc9bc423d140a6689b89c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Our observations suggest that basal tumors may exhibit broadly dec... |
QA:8d89eebc8910088d9bf8f3d5 | QAG:a39c7382cfc730a6f30d12da | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6143289? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6143289","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6143289"
] | [] | [] | [] | {"qa_id":"QA:8d89eebc8910088d9bf8f3d5","qa_group_id":"QAG:a39c7382cfc730a6f30d12da","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6143289... |
QA:8df0f22440ac39a8d6f0767c | QAG:32baceca2e8a5d3e3ee22ddc | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Here, this work included and analyzes the recent developments in engineering pancreatic tumor organoid models"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:54de3d96c31a65cbffa2e2b9","quotes":["Here, this work summarizes and analyzes the recent developments in engineeri... | [
"CLM:54de3d96c31a65cbffa2e2b9",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:37694339"
] | [
"SPAN:281a528d25d1ba337c367590"
] | [] | [] | {"qa_id":"QA:8df0f22440ac39a8d6f0767c","qa_group_id":"QAG:32baceca2e8a5d3e3ee22ddc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Here, this work included and analyzes the recent developments in e... |
QA:92c3fe518a5608df8876fbcd | QAG:35c8e57ee603efea1457a1e4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "These included mutations in STK11 and NOTCH2 , which have been previously described to have a role in PDAC carcinogenesis, and a secondary mutation in TP53, which may have been related to selective pressures induced by this patient’s prolonged therapeutic history"? Ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8de13ef27a627967f6b9810f","quotes":["These included mutations in STK11 and NOTCH2 , which have been previously de... | [
"CLM:8de13ef27a627967f6b9810f",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC5871077"
] | [
"SPAN:25c9b19fefa422a0269be0ab"
] | [] | [] | {"qa_id":"QA:92c3fe518a5608df8876fbcd","qa_group_id":"QAG:35c8e57ee603efea1457a1e4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"These included mutations in STK11 and NOTCH2 , which have been pre... |
QA:92eec4cddba5a0aec8627361 | QAG:a871df9bf336e6b93a446207 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "However, these tumor organoids can still not affected the tumor microenvironment (TME) in vivo, and the poor controllability in the preparation process hinders translation from essential drug screening to clinical pharmacological therapy"? Return the original wording w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:246e874e68cf32b8e4d8a4c6","quotes":["However, these tumor organoids can still not mimic the tumor microenvironmen... | [
"CLM:246e874e68cf32b8e4d8a4c6",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:37694339"
] | [
"SPAN:32c53a4979658ed3d8d5f655"
] | [] | [] | {"qa_id":"QA:92eec4cddba5a0aec8627361","qa_group_id":"QAG:a871df9bf336e6b93a446207","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"However, these tumor organoids can still not affected the tumor mi... |
QA:930b3be58245a9543db53295 | QAG:15848b27538c9a44c02bbeb2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Importantly, tumoral c-Jun expression was correlated with SOX9, SOX2, OCT4, FTH1, FTL and TFRC expression in consecutive PDAC tumour tissues (Fig. S 14 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:01aaf030a9c13e109bc8d208","quotes":["Importantly, tumoral c-Jun expression was positively correlated with SOX9, S... | [
"CLM:01aaf030a9c13e109bc8d208",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:1177c63aa142ace8843d4898"
] | [] | [] | {"qa_id":"QA:930b3be58245a9543db53295","qa_group_id":"QAG:15848b27538c9a44c02bbeb2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Importantly, tumoral c-Jun expression was correlated with SOX9, SO... |
QA:94374293fa430ecfb49148b2 | QAG:55c060b03ea1530ab00cc551 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In this study, we established direct co-cultures of patient-matched PDAC organoids and CAFs and showed that CAFs promoted epithelial cancer cell proliferation as well as resistance of cancer cells to gemcitabine, 5-FU and paclitaxel"? Return the original wording with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:715908db6d3167f101fb134a","quotes":["In this study, we established direct co-cultures of patient-matched PDAC org... | [
"CLM:715908db6d3167f101fb134a",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC9588250"
] | [
"SPAN:5193df55c3645716c81671b5"
] | [] | [] | {"qa_id":"QA:94374293fa430ecfb49148b2","qa_group_id":"QAG:55c060b03ea1530ab00cc551","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In this study, we established direct co-cultures of patient-matche... |
QA:95cfe71d9afdbff5912f7723 | QAG:72fd42a4ed1f292ab82f98a9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Mechanistically, we found that irbesartan decreased c-Jun expression by inhibiting the Hippo/YAP1 pathway and further overcame chemotherapy resistance in PDAC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirem... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:da645ae55381081b8673d4ea","quotes":["Mechanistically, we found that irbesartan decreased c-Jun expression by inhi... | [
"CLM:da645ae55381081b8673d4ea",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:d0fc01ee495cd3e1bda0d209"
] | [] | [] | {"qa_id":"QA:95cfe71d9afdbff5912f7723","qa_group_id":"QAG:72fd42a4ed1f292ab82f98a9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Mechanistically, we found that irbesartan decreased c-Jun expressi... |
QA:96ed3edce97b7993be7504f4 | QAG:c3de9711e5ec371df9d771d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In brief, only a strong staining of KRT81 in at least 30% of epithelial cells led to the classification of a “KRT81-positive PDAC.” Organoid lines NR002, NR005, and NR006 were derived from fine needle aspirations, so no primary tumor tissue was available to perform IHC... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:92f410f73279ce5ae1664843","quotes":["In brief, only a strong staining of KRT81 in at least 30% of epithelial cell... | [
"CLM:92f410f73279ce5ae1664843",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC6525827"
] | [
"SPAN:1d4bfac0ca42c5a0189bf3fa"
] | [] | [] | {"qa_id":"QA:96ed3edce97b7993be7504f4","qa_group_id":"QAG:c3de9711e5ec371df9d771d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In brief, only a strong staining of KRT81 in at least 30% of epith... |
QA:97208d9e535ea1f1942895d4 | QAG:efa32564ec4f299ed35cc9c9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further directly increased the responsiveness of tumour cells to chemotherapy in KPC genetically engineered mouse model; on the other hand, irbesartan also reduced desmoplasia and solid stress in PDAC... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:62f090171c1b8c7ab3921a05","quotes":["On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further... | [
"CLM:62f090171c1b8c7ab3921a05",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:56cca2ffb8dbf5d47cd5742a"
] | [] | [] | {"qa_id":"QA:97208d9e535ea1f1942895d4","qa_group_id":"QAG:efa32564ec4f299ed35cc9c9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis a... |
QA:985059da578fa7ded1b0636d | QAG:f1b54f725d1a6003d01f384e | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Irbesartan effectively decreased chemoresistance in PDAC by targeting the Hippo/YAP1/c-Jun-stemness/iron metabolism axis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pass... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1b54f9fc26c06c27607698ed","quotes":["Irbesartan effectively reduced chemoresistance in PDAC by targeting the Hipp... | [
"CLM:1b54f9fc26c06c27607698ed",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:39bc41fd7f916d09dd66e5e9"
] | [] | [] | {"qa_id":"QA:985059da578fa7ded1b0636d","qa_group_id":"QAG:f1b54f725d1a6003d01f384e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Irbesartan effectively decreased chemoresistance in PDAC by target... |
QA:9860f597afdb7e4473524ea7 | QAG:1f4bd5defc027e18a40ff5f5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "C , D Proliferation inhibition induced by gemcitabine in PDAC organoids was decreased in co-culture (AUCpi, max"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2786284b3fac77ee2930090f","quotes":["Paired t-test, * P < 0.05, ** P < 0.01. C , D Proli... | [
"CLM:2786284b3fac77ee2930090f",
"CLM:0318813e4f6821e1817a7015",
"CLM:4cda3fb211dad38b1cb55ea2"
] | [
"PMCID:PMC9588250",
"PMCID:PMC9645660"
] | [
"SPAN:30217728cd510d1c7e6e33d9",
"SPAN:b46aa9c3e528dc03aaf3c013"
] | [
"ASC2:4dae21aa11c27bb3e9503c5f"
] | [
"HYP:DCH:b8db286666a0b3c1e6c9cf7d"
] | {"qa_id":"QA:9860f597afdb7e4473524ea7","qa_group_id":"QAG:1f4bd5defc027e18a40ff5f5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"C , D Proliferation inhibition induced by gemcitabine in PDAC orga... |
QA:9b5a2ad8add75ca5463fe159 | QAG:f1c073ddacde80773f26d7c0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "7 D) improved the separation between gemcitabine drug response from two PDAC PDOs compared to GR (Fig. 7 C), which more accurately represented the clinical response of the patients treated with neoadjuvant gemcitabine-paclitaxel since PDAC_052 had a prolonged clinical ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:db029afc2293c014efb4b787","quotes":["In addition, the NDR (Fig. 7 D) improved the separa... | [
"CLM:db029afc2293c014efb4b787",
"CLM:0318813e4f6821e1817a7015",
"CLM:31f6a7c8382033a49672df34"
] | [
"PMCID:PMC10060271",
"PMCID:PMC9588250"
] | [
"SPAN:08b3e1e7e59b706fca48fec6",
"SPAN:4dbab276e46ce62231a5470e"
] | [
"ASC2:243ef55879721658a7e9fbfa"
] | [
"HYP:DCH:2e31b1d5e4ec814ea8640c3f"
] | {"qa_id":"QA:9b5a2ad8add75ca5463fe159","qa_group_id":"QAG:f1c073ddacde80773f26d7c0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"7 D) improved the separation between gemcitabine drug response fro... |
QA:9bdcbf318c9e3bec73519b52 | QAG:4b1d5a8d250538f750889387 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Results Upon co-culture with CAFs, we observed increased proliferation and reduced chemotherapy-induced cell death of PDAC organoids"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact sup... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:586d3eed931aae8e973114a5","quotes":["Results Upon co-culture with CAFs, we observed incr... | [
"CLM:586d3eed931aae8e973114a5",
"CLM:0318813e4f6821e1817a7015",
"CLM:02502f6c3387b5164c85daf1"
] | [
"PMCID:PMC9588250",
"PMCID:PMC10377599"
] | [
"SPAN:6f80dc0e6d12da352891e4ef",
"SPAN:6298eeccbe1a49d476af9748"
] | [
"ASC2:969861fff86ee9732e049aa4"
] | [
"HYP:DCH:e9534fd38ad679d0f2216646"
] | {"qa_id":"QA:9bdcbf318c9e3bec73519b52","qa_group_id":"QAG:4b1d5a8d250538f750889387","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Results Upon co-culture with CAFs, we observed increased prolifera... |
QA:a3ba58905edea851d820f99e | QAG:73e13c32c6f4a23b0632c020 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "C , D Proliferation inhibition promoted by gemcitabine in PDAC organoids was significantly reduced in co-culture (AUCpi, max"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c32b480eff66da45d7742e45","quotes":["Paired t-test, * P < 0.05, ** P < 0.01. C , D Proliferation inhibition induc... | [
"CLM:c32b480eff66da45d7742e45",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC9588250"
] | [
"SPAN:30217728cd510d1c7e6e33d9"
] | [] | [] | {"qa_id":"QA:a3ba58905edea851d820f99e","qa_group_id":"QAG:73e13c32c6f4a23b0632c020","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"C , D Proliferation inhibition promoted by gemcitabine in PDAC org... |
QA:a58ba7b22696b6d2bcf37dbf | QAG:b93f2ee42a1e6742e0c0ddd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "These included mutations in STK11 and NOTCH2 , which have been previously described to have a role in PDAC carcinogenesis, and a secondary mutation in TP53, which may have been related to selective pressures promoted by this patient’s prolonged therapeutic history"? Re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c10b7f7788f5bb955aed6f54","quotes":["These included mutations in STK11 and NOTCH2 , which have been previously de... | [
"CLM:c10b7f7788f5bb955aed6f54",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC5871077"
] | [
"SPAN:25c9b19fefa422a0269be0ab"
] | [] | [] | {"qa_id":"QA:a58ba7b22696b6d2bcf37dbf","qa_group_id":"QAG:b93f2ee42a1e6742e0c0ddd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"These included mutations in STK11 and NOTCH2 , which have been pre... |
QA:a68e3a766b4740294816f805 | QAG:c1d371fadedbf25e0d57a9bf | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "This vast tumor ECM forms a physical barrier that can lead to decreased drug delivery to tumor cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:be382d7664cda3cae054ee29","quotes":["This vast tumor ECM forms a physical barrier that can lead to decreased drug... | [
"CLM:be382d7664cda3cae054ee29",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC9588250"
] | [
"SPAN:1bcf19450ec9813d447600bb",
"SPAN:9bca2f839cbd6368581e2658"
] | [] | [] | {"qa_id":"QA:a68e3a766b4740294816f805","qa_group_id":"QAG:c1d371fadedbf25e0d57a9bf","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"This vast tumor ECM forms a physical barrier that can lead to decr... |
QA:a6cf4728b0f38218a1c969e8 | QAG:8b5feef922d3ee5ea07ea7a2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "To address whether the different molecular subtypes exhibit a differential drug response towards conventional chemotherapeutics, PDAC organoids received gemcitabine and the single drug compounds of the FOLFIRINOX regimens, irinotecan, oxaliplatin, and 5-FU ( Figure 4(a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bdc47ee128bed46c88809384","quotes":["To address whether the different molecular subtypes... | [
"CLM:bdc47ee128bed46c88809384",
"CLM:0318813e4f6821e1817a7015",
"CLM:251c4a58d8be4691cf9dce11"
] | [
"PMCID:PMC6525827",
"PMCID:PMC10157938"
] | [
"SPAN:71312f60dc1686dba71e33a9",
"SPAN:0810c5320b2ce055856c748e"
] | [
"ASC2:e460df608e6207f60e9fcf20"
] | [
"HYP:DCH:7129d478c9553d386522f71b"
] | {"qa_id":"QA:a6cf4728b0f38218a1c969e8","qa_group_id":"QAG:8b5feef922d3ee5ea07ea7a2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"To address whether the different molecular subtypes exhibit a diff... |
QA:ae3598e25802f416dce72ec9 | QAG:549b579188c6f534f4ec3a3b | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "reported that PDAC cells showed elevated iron metabolism levels compared to adjacent normal cells, and that the iron chelator deferoxamine (DFO) decreased the tumour burden of PDAC by decreasing iron metabolism"? Return the original wording with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6f751b87e094027c6603052f","quotes":["Jiayan Lang et al. reported that PDAC cells showed elevated iron metabolism ... | [
"CLM:6f751b87e094027c6603052f",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:5a23fbe7d55fa46ea8d92139"
] | [] | [] | {"qa_id":"QA:ae3598e25802f416dce72ec9","qa_group_id":"QAG:549b579188c6f534f4ec3a3b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"reported that PDAC cells showed elevated iron metabolism levels co... |
QA:b149e27f8ad9bfe8a4bc6b42 | QAG:e6606a0120f89e63686e09b9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Furthermore, in accordance with the high metastatic burden in PDAC, it is well described in previous studies that chemotherapy promoted stress might promote invasion and EMT 41 – 44"? Return the original wording with paper, Claim, and Evidence Span references.
Integra... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cba2643c61319a5f18e32b5d","quotes":["Furthermore, in accordance with the high metastatic burden in PDAC, it is we... | [
"CLM:cba2643c61319a5f18e32b5d",
"CLM:065ed27ad3615b0a901fd1b8"
] | [
"PMCID:PMC10709344"
] | [
"SPAN:9e229fca8a7f04139a0aeb9d"
] | [] | [] | {"qa_id":"QA:b149e27f8ad9bfe8a4bc6b42","qa_group_id":"QAG:e6606a0120f89e63686e09b9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Furthermore, in accordance with the high metastatic burden in PDAC... |
QA:b28496206f1e6e1f6bd2fc32 | QAG:e34e43302882d506e7246996 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "The use of a positive and negative control and the normalized drug response, as developed by Gupta and colleagues led to the best discrimination in gemcitabine drug response between two PDAC patients with varying clinical outcomes following neoadjuvant gemcitabine-pacl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1d034a217cdc8e6c24a4fd7c","quotes":["The use of a positive and negative control and the normalized drug response,... | [
"CLM:1d034a217cdc8e6c24a4fd7c",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10060271"
] | [
"SPAN:b7509a08900075a0a4ce229b"
] | [] | [] | {"qa_id":"QA:b28496206f1e6e1f6bd2fc32","qa_group_id":"QAG:e34e43302882d506e7246996","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"The use of a positive and negative control and the normalized drug... |
QA:b50095d683057c5e6d13ebc9 | QAG:02384e3d26cde706adf008f2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Similar results were obtained in Cohort4#, which contained 60 patients with advanced (stage III/IV) PDAC who received GEM/nab-paclitaxel chemotherapy at Tongliao City Hospital and were also diagnosed with hypertension (Fig. 11 J)"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b56b6f8a530d79f7213688ac","quotes":["Similar results were obtained in Cohort4#, which contained 60 patients with ... | [
"CLM:b56b6f8a530d79f7213688ac",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:a1cdb29d162edca6cde48e75"
] | [] | [] | {"qa_id":"QA:b50095d683057c5e6d13ebc9","qa_group_id":"QAG:02384e3d26cde706adf008f2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Similar results were obtained in Cohort4#, which contained 60 pati... |
QA:b591c1d22db4512513d70c70 | QAG:3030b70a2e28629bcfc0a848 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In summary, these results were highly consistent with our in vitro and in vivo studies showing that tumoral c-Jun expression was correlated with the response to chemotherapy in PDAC patients"? Return the original wording with paper, Claim, and Evidence Span references.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1493a8f2c1633012638397fa","quotes":["In summary, these results were highly consistent with our in vitro and in vi... | [
"CLM:1493a8f2c1633012638397fa",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:76aaac951588263676cdde2b"
] | [] | [] | {"qa_id":"QA:b591c1d22db4512513d70c70","qa_group_id":"QAG:3030b70a2e28629bcfc0a848","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In summary, these results were highly consistent with our in vitro... |
QA:b71e501e7c728b79617fa3f4 | QAG:1781b298c706323c1c035fd6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Tumor latency duration was not associated with tumor cellularity (Supplementary Fig. S2 F).The growth rates in the PDAC subset was not significantly associated with clinical outcome (Supplementary Fig S3 A,B)"? Return the original wording with paper, Claim, and Evidenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:79caa1d960a55ad87d107d10","quotes":["Tumor latency duration was not associated with tumor cellularity (Supplement... | [
"CLM:79caa1d960a55ad87d107d10",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC8134568"
] | [
"SPAN:953bda6fe8947fadeeb43b70"
] | [] | [] | {"qa_id":"QA:b71e501e7c728b79617fa3f4","qa_group_id":"QAG:1781b298c706323c1c035fd6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Tumor latency duration was not associated with tumor cellularity (... |
QA:bb0cf1e880ec590e894f2ca5 | QAG:eb4109d51c444da0ec3f1a79 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "The growth rates in the PDAC subset was not associated with clinical outcome (Supplementary Fig S3 A,B)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, C... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:81b6d159eff6223342b79b0f","quotes":["Tumor latency duration was not associated with tumor cellularity (Supplement... | [
"CLM:81b6d159eff6223342b79b0f",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC8134568"
] | [
"SPAN:953bda6fe8947fadeeb43b70"
] | [] | [] | {"qa_id":"QA:bb0cf1e880ec590e894f2ca5","qa_group_id":"QAG:eb4109d51c444da0ec3f1a79","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"The growth rates in the PDAC subset was not associated with clinic... |
QA:bcb5d0bf854102e72fe30ca6 | QAG:d1a6dc096b1fca7af5d034f3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "CD44 signaling has also been shown to promote stemness via a SPP1-CD44 axis and high expression of CD44 was associated with poor prognosis in PDAC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a7fb121adcb2d5d476a4e861","quotes":["CD44 signaling has also been shown to promote stemness via a SPP1-CD44 axis ... | [
"CLM:a7fb121adcb2d5d476a4e861",
"CLM:0595c56a1ea6580a9230d904"
] | [
"PMCID:PMC9588250"
] | [
"SPAN:3dd6e0b7d79e1aa83c8a12a3"
] | [] | [] | {"qa_id":"QA:bcb5d0bf854102e72fe30ca6","qa_group_id":"QAG:d1a6dc096b1fca7af5d034f3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"CD44 signaling has also been shown to promote stemness via a SPP1-... |
QA:bccde5ced6178dfc9f38838c | QAG:89ad803d3499630d003e3113 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In addition, the future direction of improving engineered pancreatic cancer organoids is included for their application prospects in clinical treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cb835890356d59cb17adbfc2","quotes":["In addition, the future direction of improving engineered pancreatic cancer ... | [
"CLM:cb835890356d59cb17adbfc2",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:37694339"
] | [
"SPAN:608037e034dd2b5e875d9436"
] | [] | [] | {"qa_id":"QA:bccde5ced6178dfc9f38838c","qa_group_id":"QAG:89ad803d3499630d003e3113","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In addition, the future direction of improving engineered pancreat... |
QA:be619ed0a3ab4e411cfd7f7b | QAG:347c61afe1cde302a89d5c59 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "The results of the TUNEL assay and Ki67 immunofluorescence staining in mouse pancreatic tumor indicated that a higher proliferative capacity and lower apoptotic rate in PDO-c-Jun-OE tumors than in PDO-vector tumors, and that c-Jun overexpression increased the resistanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:251c4a58d8be4691cf9dce11","quotes":["The results of the TUNEL assay and Ki67 immunofluor... | [
"CLM:251c4a58d8be4691cf9dce11",
"CLM:0318813e4f6821e1817a7015",
"CLM:2786284b3fac77ee2930090f"
] | [
"PMCID:PMC10157938",
"PMCID:PMC9588250"
] | [
"SPAN:0810c5320b2ce055856c748e",
"SPAN:30217728cd510d1c7e6e33d9"
] | [
"ASC2:0a05436930a0ea2042dabdce"
] | [] | {"qa_id":"QA:be619ed0a3ab4e411cfd7f7b","qa_group_id":"QAG:347c61afe1cde302a89d5c59","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"The results of the TUNEL assay and Ki67 immunofluorescence stainin... |
QA:bf5803aa216a2f81ba0a6dac | QAG:f0d5b3eb2fbff88e0473d2d1 | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36343611? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:36343611","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:36343611"
] | [] | [] | [] | {"qa_id":"QA:bf5803aa216a2f81ba0a6dac","qa_group_id":"QAG:f0d5b3eb2fbff88e0473d2d1","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36343611? E... |
QA:c2f906a3ab71a2665fb044c4 | QAG:49d8ce383afa774b128f037d | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "The strained cell pellet was resuspended in >80% ice-cold Cultrex growth factor decreased BME type 2 (R&D Systems) in PDAC organoid medium"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5b66aa90be539095833c9e27","quotes":["The strained cell pellet was resuspended in >80% ice-cold Cultrex growth fac... | [
"CLM:5b66aa90be539095833c9e27",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10709344"
] | [
"SPAN:b53c9cd3ca6e61738c073772"
] | [] | [] | {"qa_id":"QA:c2f906a3ab71a2665fb044c4","qa_group_id":"QAG:49d8ce383afa774b128f037d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"The strained cell pellet was resuspended in >80% ice-cold Cultrex ... |
QA:c9a11068f6def5ef812512bf | QAG:9f923c9d3cbe87a6499ea00c | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "on the other hand, irbesartan also decreased desmoplasia and solid stress in PDAC tumors and further increased the therapeutic drug diffusion"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:741f0fbc6073ce65866b47e7","quotes":["On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further... | [
"CLM:741f0fbc6073ce65866b47e7",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:56cca2ffb8dbf5d47cd5742a"
] | [] | [] | {"qa_id":"QA:c9a11068f6def5ef812512bf","qa_group_id":"QAG:9f923c9d3cbe87a6499ea00c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"on the other hand, irbesartan also decreased desmoplasia and solid... |
QA:cede59e58739273eb39afba1 | QAG:666d50b789ed5566f3857315 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "On the one hand, irbesartan inhibited the Hippo/YAP1/c-Jun axis and further directly enhanced the responsiveness of tumour cells to chemotherapy in KPC genetically engineered mouse model; on the other hand, irbesartan also reduced desmoplasia and solid stress in PDAC t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a5c41cf43e1561359c3dbb98","quotes":["On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further... | [
"CLM:a5c41cf43e1561359c3dbb98",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:56cca2ffb8dbf5d47cd5742a"
] | [] | [] | {"qa_id":"QA:cede59e58739273eb39afba1","qa_group_id":"QAG:666d50b789ed5566f3857315","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"On the one hand, irbesartan inhibited the Hippo/YAP1/c-Jun axis an... |
QA:d150fd1999dae63986d514bc | QAG:13ac8c43d6f1ff8c51c02ac0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "However, these tumor organoids can still not mimic the tumor microenvironment (TME) in vivo, and the poor controllability in the preparation process affected translation from essential drug screening to clinical pharmacological therapy"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ac62e6421b57d61a145d9dbf","quotes":["However, these tumor organoids can still not mimic the tumor microenvironmen... | [
"CLM:ac62e6421b57d61a145d9dbf",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:37694339"
] | [
"SPAN:32c53a4979658ed3d8d5f655"
] | [] | [] | {"qa_id":"QA:d150fd1999dae63986d514bc","qa_group_id":"QAG:13ac8c43d6f1ff8c51c02ac0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"However, these tumor organoids can still not mimic the tumor micro... |
QA:d370efcca191ae5408b57c1b | QAG:57b780764a972c4103ca08a1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Organoids, 3-dimensional (3D) cultures of neoplastic cells derived from primary tumor specimens represented an ideal platform for these types of studies because benchtop protocols previously developed for 2-dimensional cell lines can be adapted for use"? Return the ori... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dd5538c28c60e5ac259033df","quotes":["Organoids, 3-dimensional (3D) cultures of neoplastic cells derived from prim... | [
"CLM:dd5538c28c60e5ac259033df",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:29736724"
] | [
"SPAN:c92a1edc9679442773e58c0e"
] | [] | [] | {"qa_id":"QA:d370efcca191ae5408b57c1b","qa_group_id":"QAG:57b780764a972c4103ca08a1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Organoids, 3-dimensional (3D) cultures of neoplastic cells derived... |
QA:d535e06ed868d9cb91c5d863 | QAG:fe8a4a1bf20a5d8998b86e19 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "To further validate the above findings, we first collected and analyzed the IHC and clinical data from PDAC patients in Cohort 1#, who received the current GEM plus nab-paclitaxel regimen as postoperative adjuvant chemotherapy"? Return the original wording with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dbf3e28dd38829976ea56ae3","quotes":["To further validate the above findings, we first collected and analyzed the ... | [
"CLM:dbf3e28dd38829976ea56ae3",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:1dea5b08d316e3bf8f321d05"
] | [] | [] | {"qa_id":"QA:d535e06ed868d9cb91c5d863","qa_group_id":"QAG:fe8a4a1bf20a5d8998b86e19","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"To further validate the above findings, we first collected and ana... |
QA:d6819a61b12dcaf79e8e5f40 | QAG:6f8c3bc194f5ce474f30ad98 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Obesity promoted Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:371df87774a7f84d84ef3999","quotes":["28. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-Indu... | [
"CLM:371df87774a7f84d84ef3999",
"CLM:04370c21ee42323f87a07bc7"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:3b29c326eb4e3c6fd597896b"
] | [] | [] | {"qa_id":"QA:d6819a61b12dcaf79e8e5f40","qa_group_id":"QAG:6f8c3bc194f5ce474f30ad98","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Obesity promoted Inflammation and Desmoplasia Promote Pancreatic C... |
QA:d6c14ed26abebc6b1d185080 | QAG:624e916057feae1b945906df | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "found that high expression of c-Jun/AP-1 was linked to poorly differentiated/basal subtype lesions, which predicted an overall unfavorable prognosis and resistance to therapy in PDAC"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7d9d446cd756a372069555ac","quotes":["After analyzing the gene expression patterns in tumors from a KrasG12D; p53R... | [
"CLM:7d9d446cd756a372069555ac",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:2a04cbf77fa5b7708b26d9e6"
] | [] | [] | {"qa_id":"QA:d6c14ed26abebc6b1d185080","qa_group_id":"QAG:624e916057feae1b945906df","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"found that high expression of c-Jun/AP-1 was linked to poorly diff... |
QA:d97dfcf9c0d8a7ffcae651aa | QAG:c5985680b4a5debf463e6b7b | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Several studies have shown increased therapeutic resistance in PDAC under the influence of CAFs in vitro , suggesting that improved modelling of the tumor stroma might have an impact on the predictive capabilities of organoid cultures"? Return the original wording with... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:02502f6c3387b5164c85daf1","quotes":["Several studies have shown increased therapeutic resistance in PDAC under th... | [
"CLM:02502f6c3387b5164c85daf1",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10377599"
] | [
"SPAN:6298eeccbe1a49d476af9748"
] | [] | [] | {"qa_id":"QA:d97dfcf9c0d8a7ffcae651aa","qa_group_id":"QAG:c5985680b4a5debf463e6b7b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Several studies have shown increased therapeutic resistance in PDA... |
QA:da8caa5ee4ef24dcafb7b336 | QAG:ede5731b000c02642c17e2b3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In addition, the KRAS mutant PDAC_052 and PDAC_060 lines were included as genetically validated tumor organoids (Fig. S2 (SM9), Table 1 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exac... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9bdbcdd17f08cdc31ff7ea78","quotes":["In addition, the KRAS mutant PDAC_052 and PDAC_060 ... | [
"CLM:9bdbcdd17f08cdc31ff7ea78",
"CLM:0595c56a1ea6580a9230d904",
"CLM:6314e337413af655973a0780"
] | [
"PMCID:PMC10060271",
"PMCID:PMC9289822"
] | [
"SPAN:178c0c5e9e75eb3cc5910ded",
"SPAN:125037a602c041b856e1c871"
] | [
"ASC2:2691d4b104fa25588e8fef82"
] | [
"HYP:DCH:6e00ea04f172f6efa4e717ec"
] | {"qa_id":"QA:da8caa5ee4ef24dcafb7b336","qa_group_id":"QAG:ede5731b000c02642c17e2b3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In addition, the KRAS mutant PDAC_052 and PDAC_060 lines were incl... |
QA:db0b70f77d15371675fc1c69 | QAG:5fc66caf2a6c9bb927ebfbd7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Another retrospective cohort containing 58 patients who had received radical surgical R0 resection with a histological diagnosis of PDAC at the Tianjin Medical University Cancer Institute and Hospital, China, between April 2012 and December 2020 were enrolled in this s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91eaf80eff315ba86493a985","quotes":["Another retrospective cohort containing 58 patients who had received radical... | [
"CLM:91eaf80eff315ba86493a985",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:c32775e900c554c2d08e7322"
] | [] | [] | {"qa_id":"QA:db0b70f77d15371675fc1c69","qa_group_id":"QAG:5fc66caf2a6c9bb927ebfbd7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Another retrospective cohort containing 58 patients who had receiv... |
QA:de82e98c52ca31fba6632421 | QAG:c1546e6e121d8f93b8274b98 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "In this protocol established tumor-derived organoid cultures are dissociated into single cells, plated in a 3D gel matrix, and exposed to pharmacologic agents"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirem... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3cdb1354d37138df39228af2","quotes":["In this protocol, established tumor-derived organoid cultures are dissociate... | [
"CLM:3cdb1354d37138df39228af2",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMID:29736724"
] | [
"SPAN:24ac69811019bcd65a4f5183"
] | [] | [] | {"qa_id":"QA:de82e98c52ca31fba6632421","qa_group_id":"QAG:c1546e6e121d8f93b8274b98","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"In this protocol established tumor-derived organoid cultures are d... |
QA:e44b14328e1f6efd46547876 | QAG:621c98dab6f321054080e5ba | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Several studies have shown increased therapeutic resistance in PDAC under the influence of CAFs in vitro , suggesting that improved modelling of the tumor stroma might have an impact on the predictive capabilities of organoid cultures"? Return the original wording with... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:44801c66ff772549f4098a73","quotes":["Several studies have shown increased therapeutic resistance in PDAC under th... | [
"CLM:44801c66ff772549f4098a73",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10377599"
] | [
"SPAN:6298eeccbe1a49d476af9748"
] | [] | [] | {"qa_id":"QA:e44b14328e1f6efd46547876","qa_group_id":"QAG:621c98dab6f321054080e5ba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Several studies have shown increased therapeutic resistance in PDA... |
QA:e4e31279e33fd160b7ab70df | QAG:7455fd1d0c5beef251e46db1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Another retrospective cohort containing 58 patients who had received radical surgical R0 resection with a histological diagnosis of PDAC at the Tianjin Medical University Cancer Institute and Hospital, China, between April 2012 and December 2020 was enrolled in this st... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3138658f8193739bd2223ca5","quotes":["Another retrospective cohort containing 58 patients who had received radical... | [
"CLM:3138658f8193739bd2223ca5",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:c32775e900c554c2d08e7322"
] | [] | [] | {"qa_id":"QA:e4e31279e33fd160b7ab70df","qa_group_id":"QAG:7455fd1d0c5beef251e46db1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Another retrospective cohort containing 58 patients who had receiv... |
QA:e4f74f5569d576588774db30 | QAG:17748ec75bf3c0dab13a8180 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "’s observation 31 that the somatic variant concordance between primary tumors and corresponding organoids led to an average 88.1%, in 12 cancer types"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6314e337413af655973a0780","quotes":["The results indicated that the organoid from EUS-FNA retained about 93% of t... | [
"CLM:6314e337413af655973a0780",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC9289822"
] | [
"SPAN:125037a602c041b856e1c871"
] | [] | [] | {"qa_id":"QA:e4f74f5569d576588774db30","qa_group_id":"QAG:17748ec75bf3c0dab13a8180","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"’s observation 31 that the somatic variant concordance between pri... |
QA:e6ff509d63ee6a25c01d035d | QAG:84bdca91ea6101e024c26369 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "( A ) Heat map of the activity of 114 NCI oncology drugs associated with each of the four pancreatic cancer-associated cells in 3D and 2D formats assessed by corresponding log IC 50 values (red = increased potency; green = decreased potency)"? Return the original wordi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d94697621be66b66644f1ae0","quotes":["Figure 3. ( A ) Heat map of the activity of 114 NCI oncology drugs associate... | [
"CLM:d94697621be66b66644f1ae0",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC6013403"
] | [
"SPAN:22d31e8f29ab06783fc36ce7"
] | [] | [] | {"qa_id":"QA:e6ff509d63ee6a25c01d035d","qa_group_id":"QAG:84bdca91ea6101e024c26369","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"( A ) Heat map of the activity of 114 NCI oncology drugs associate... |
QA:e7236ae2259c3cb04418963e | QAG:8c29040e3f0ff332f4d751f7 | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6647028? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6647028","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6647028"
] | [] | [] | [] | {"qa_id":"QA:e7236ae2259c3cb04418963e","qa_group_id":"QAG:8c29040e3f0ff332f4d751f7","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6647028... |
QA:f03456853ca26f89cd864487 | QAG:93faf1c099eec701292f0211 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Optical imaging of drug promoted metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9db0535c61d4c5a0bba2fbf7","quotes":["Optical imaging of drug-induced metabolism changes in murine and human pancr... | [
"CLM:9db0535c61d4c5a0bba2fbf7",
"CLM:01aaf030a9c13e109bc8d208"
] | [
"PMCID:PMC6906216"
] | [
"SPAN:d4e0b10ea63dfcf33ce60491"
] | [] | [] | {"qa_id":"QA:f03456853ca26f89cd864487","qa_group_id":"QAG:93faf1c099eec701292f0211","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Optical imaging of drug promoted metabolism changes in murine and ... |
QA:f03b71d162e245b02b70fc18 | QAG:dbeea0cdc092af8494346d03 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "reported that PDAC cells showed increased iron metabolism levels compared to adjacent normal cells, and that the iron chelator deferoxamine (DFO) significantly reduced the tumour burden of PDAC by decreasing iron metabolism"? Return the original wording with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0073e43d7fb8ff1117fb197c","quotes":["Jiayan Lang et al. reported that PDAC cells showed elevated iron metabolism ... | [
"CLM:0073e43d7fb8ff1117fb197c",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:5a23fbe7d55fa46ea8d92139"
] | [] | [] | {"qa_id":"QA:f03b71d162e245b02b70fc18","qa_group_id":"QAG:dbeea0cdc092af8494346d03","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"reported that PDAC cells showed increased iron metabolism levels c... |
QA:f2c2e58fde1b26e73671779c | QAG:a70cc7299e932ae6865b4bb5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "The patient received an infusion of T cells (10 10 cells /m 2 : total 19 billion PCAA, pancreatic cancer associated antigen-specific CTL) 30 days apart, each followed by low-dose subcutaneous (s.c.) IL-2 (250,000 U/m 2 every 12h) and anti-PD1 every 3 weeks"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:065ed27ad3615b0a901fd1b8","quotes":["The patient received an infusion of T cells (10 10 cells /m 2 : total 19 bil... | [
"CLM:065ed27ad3615b0a901fd1b8",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC5871077"
] | [
"SPAN:84847c8ca2a5d314583ad51d"
] | [] | [] | {"qa_id":"QA:f2c2e58fde1b26e73671779c","qa_group_id":"QAG:a70cc7299e932ae6865b4bb5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"The patient received an infusion of T cells (10 10 cells /m 2 : to... |
QA:f349b1129b4daced18d0adfa | QAG:15c626883fe6ff407e94816b | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Ex vivo PDO pharmacotyping with FFX components predicted clinical therapeutic response in these patients with borderline resectable or locally advanced PDAC treated in a neoadjuvant or induction paradigm"? Return the original wording with paper, Claim, and Evidence Spa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fecc7bb8f9e9fc8e693bfc4a","quotes":["Ex vivo PDO pharmacotyping with FFX components predicted clinical therapeuti... | [
"CLM:fecc7bb8f9e9fc8e693bfc4a",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC9357072"
] | [
"SPAN:6e64547a3d6f2215d2b8e892"
] | [] | [] | {"qa_id":"QA:f349b1129b4daced18d0adfa","qa_group_id":"QAG:15c626883fe6ff407e94816b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Ex vivo PDO pharmacotyping with FFX components predicted clinical ... |
QA:f76e2be0b8ea5a6b604067fa | QAG:405c289f7d5ae377064ff69a | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "High in vitro sensitivity to standard-of-care chemotherapeutics predicted good clinical response to systemic chemotherapy in PDAC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:68e9c2077aace8a333269fa5","quotes":["High in vitro sensitivity to standard-of-care chemotherapeutics predicts goo... | [
"CLM:68e9c2077aace8a333269fa5",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC9357072"
] | [
"SPAN:f378eab528a496cfe063225d"
] | [] | [] | {"qa_id":"QA:f76e2be0b8ea5a6b604067fa","qa_group_id":"QAG:405c289f7d5ae377064ff69a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"High in vitro sensitivity to standard-of-care chemotherapeutics pr... |
QA:f7be546084ef1214c73e59d9 | QAG:75bcdc3872d28a91992cd02a | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6936689? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6936689","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6936689"
] | [] | [] | [] | {"qa_id":"QA:f7be546084ef1214c73e59d9","qa_group_id":"QAG:75bcdc3872d28a91992cd02a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6936689... |
QA:f8dd1652173b29f93805e5ff | QAG:e7b35136da7be17052a224e2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "PDAC organoids received serial dilutions of gemcitabine (3nM-1000nM), an FDA-approved chemotherapeutic agent commonly used to treat pancreatic cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4cda3fb211dad38b1cb55ea2","quotes":["PDAC organoids were treated with serial dilutions o... | [
"CLM:4cda3fb211dad38b1cb55ea2",
"CLM:0318813e4f6821e1817a7015",
"CLM:48c63c07ec6922389d8f68f8"
] | [
"PMCID:PMC9645660",
"PMCID:PMC10157938"
] | [
"SPAN:b46aa9c3e528dc03aaf3c013",
"SPAN:09c4b4174e3289dceed43948"
] | [
"ASC2:85d16d90b838b8ef5d3c5959"
] | [
"HYP:DCH:ce2e44b105b58d74e65b52c7"
] | {"qa_id":"QA:f8dd1652173b29f93805e5ff","qa_group_id":"QAG:e7b35136da7be17052a224e2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"PDAC organoids received serial dilutions of gemcitabine (3nM-1000n... |
QA:fb3bf247d738ba839d050a5a | QAG:daa3fc9ee8118f26b1b91002 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "Optical imaging of drug promoted metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:93452c87c29c4a49463a1474","quotes":["Optical imaging of drug-induced metabolism changes in murine and human pancr... | [
"CLM:93452c87c29c4a49463a1474",
"CLM:01aaf030a9c13e109bc8d208"
] | [
"PMCID:PMC7710298"
] | [
"SPAN:4aef9557901977ca5def503e"
] | [] | [] | {"qa_id":"QA:fb3bf247d738ba839d050a5a","qa_group_id":"QAG:daa3fc9ee8118f26b1b91002","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"Optical imaging of drug promoted metabolism changes in murine and ... |
QA:fb530114b0511fd64fa87bf7 | QAG:17bdedf7160e3653e7b01991 | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "on the other hand, irbesartan also reduced desmoplasia and solid stress in PDAC tumors and further increased the therapeutic drug diffusion"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ex... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d0235c3980fa16c5d9f26ae2","quotes":["On the one hand, irbesartan suppressed the Hippo/YAP1/c-Jun axis and further... | [
"CLM:d0235c3980fa16c5d9f26ae2",
"CLM:0318813e4f6821e1817a7015"
] | [
"PMCID:PMC10157938"
] | [
"SPAN:56cca2ffb8dbf5d47cd5742a"
] | [] | [] | {"qa_id":"QA:fb530114b0511fd64fa87bf7","qa_group_id":"QAG:17bdedf7160e3653e7b01991","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"on the other hand, irbesartan also reduced desmoplasia and solid s... |
QA:fb83faf539deba059ac04652 | QAG:8a10460c18721781df57350c | provenance_qa | exact_evidence_retrieval | provenance_qa | G021 | en | train | Which exact source passage supports the statement "However, in this study, the expression of AREG increased in pancreatic cancer cells along with tumor development, as revealed by analyzing sequential single-cell transcriptome analysis of mouse pancreatic cancer development"? Return the original wording with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e3db3f0338b16a7793cc4bd4","quotes":["However, in this study, the expression of AREG increased in pancreatic cance... | [
"CLM:e3db3f0338b16a7793cc4bd4",
"CLM:0073e43d7fb8ff1117fb197c"
] | [
"PMCID:PMC10411021"
] | [
"SPAN:33d55e101a119e5eee79c292"
] | [] | [] | {"qa_id":"QA:fb83faf539deba059ac04652","qa_group_id":"QAG:8a10460c18721781df57350c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G021","question":"Which exact source passage supports the statement \"However, in this study, the expression of AREG increased in pancre... |
QA:ffabe88ed4dd2f2bf71275fc | QAG:ef8b972264602a10f7004990 | provenance_qa | paper_evidence_availability | provenance_qa | G021 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8301364? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8301364","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8301364"
] | [] | [] | [] | {"qa_id":"QA:ffabe88ed4dd2f2bf71275fc","qa_group_id":"QAG:ef8b972264602a10f7004990","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G021","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8301364... |
QA:031ac2e090021aaf240cd1d4 | QAG:918ba80d26f286c5241b58ed | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Figure 5 decreased OTUD6B predicts a poor prognosis in ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references;... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ae7a89c9094a421e4c64728b","quotes":["Figure 5 Reduced OTUD6B predicts a poor prognosis in ESCC patients."],"citat... | [
"CLM:ae7a89c9094a421e4c64728b",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:e8735eaa80b9b68a4d823fc3"
] | [] | [] | {"qa_id":"QA:031ac2e090021aaf240cd1d4","qa_group_id":"QAG:918ba80d26f286c5241b58ed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Figure 5 decreased OTUD6B predicts a poor prognosis in ESCC patien... |
QA:035825cef106e93bda4b89ab | QAG:3e79ddb52557886a98f6db77 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "We found that knockdown of RAR α significantly increased the protein level of OTUD6B in ESCC cells, while ectopic expression of RAR α decreased it (Figure 6K,L )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0dd3c5cea2d9fd6defdc9e63","quotes":["We found that knockdown of RAR α significantly increased the protein level o... | [
"CLM:0dd3c5cea2d9fd6defdc9e63",
"CLM:0c6c6d10a7936920ba93324f"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:481673354cb69ce44d49e9f7"
] | [] | [] | {"qa_id":"QA:035825cef106e93bda4b89ab","qa_group_id":"QAG:3e79ddb52557886a98f6db77","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"We found that knockdown of RAR α significantly increased the prote... |
QA:04ea51037bacc4614e1f305e | QAG:192da09ce0f2962c178932b8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Immunotherapy combined with chemotherapy has been studied by CheckMate 649 ( 21 ), KEYNOTE-590 ( 22 ), and ESCORT-1st ( 23 ) as the 1st-line treatment for advanced esophageal cancer, and was found to improved OS compared to chemotherapy alone"? Return the original word... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:681e7004b7d2f4c3fc359bd8","quotes":["Immunotherapy combined with chemotherapy has been studied by CheckMate 649 (... | [
"CLM:681e7004b7d2f4c3fc359bd8",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:ee4a4295475063078e216767"
] | [] | [] | {"qa_id":"QA:04ea51037bacc4614e1f305e","qa_group_id":"QAG:192da09ce0f2962c178932b8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Immunotherapy combined with chemotherapy has been studied by Check... |
QA:065158729b3b999cf7c27783 | QAG:ba383cf18c39d91d61d596b6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Among all ESCC patients who received ICIs+chemotherapy, 1318 patients had measurable lesions"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e8a371cf048077437fce6a5a","quotes":["Among all ESCC patients who received ICIs+chemotherapy, 1318 patients had me... | [
"CLM:e8a371cf048077437fce6a5a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:7cb359c4a3396f5b1c9f73ed"
] | [] | [] | {"qa_id":"QA:065158729b3b999cf7c27783","qa_group_id":"QAG:ba383cf18c39d91d61d596b6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Among all ESCC patients who received ICIs+chemotherapy, 1318 patie... |
QA:08524fcabab543f0a1ed6c5f | QAG:e047233a6ea75cd2c4197542 | provenance_qa | paper_evidence_availability | provenance_qa | G023 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35595021? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35595021","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35595021"
] | [] | [] | [] | {"qa_id":"QA:08524fcabab543f0a1ed6c5f","qa_group_id":"QAG:e047233a6ea75cd2c4197542","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G023","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35595021? E... |
QA:092b65f8eb66dba3148c90ed | QAG:52a839f5dc669301c63e6393 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with placebo plus chemotherapy, ICIs plus chemotherapy improved the OS of ESCC patients in whole population (pooled HR=0.69; 95% CI, 0.63–0.76; p<0.01) ( Figure 2 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prov... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bf41910086aa355807d4b6be","quotes":["Compared with placebo plus chemotherapy, ICIs plus chemotherapy significantl... | [
"CLM:bf41910086aa355807d4b6be",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:4f10d78854a2fa42aa3da31d"
] | [] | [] | {"qa_id":"QA:092b65f8eb66dba3148c90ed","qa_group_id":"QAG:52a839f5dc669301c63e6393","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with placebo plus chemotherapy, ICIs plus chemotherapy im... |
QA:09cfd375a8c1c11a3fff3a05 | QAG:edc625a8856119d4c777b380 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "8a,b ), although the latter promoted more pathological regression preoperatively (pCR rate of 30%)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d9a8fc2a1e1469200f03db3d","quotes":["Moreover, preliminary evidence revealed that 2-year OS in NATION-1907 was su... | [
"CLM:d9a8fc2a1e1469200f03db3d",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10427424"
] | [
"SPAN:b10fba05a58b56a4f2e86989"
] | [] | [] | {"qa_id":"QA:09cfd375a8c1c11a3fff3a05","qa_group_id":"QAG:edc625a8856119d4c777b380","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"8a,b ), although the latter promoted more pathological regression ... |
QA:0ae423913e6a8b4b54fbb6bd | QAG:338b1dd00bb29ad3a9b5643f | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "5 Compared with standard chemotherapy, PD-1 inhibitor-based therapy led to a significantly better survival benefit in patients with ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:16d4b69a4ad9504c16cf2c35","quotes":["5 Compared with standard c... | [
"CLM:16d4b69a4ad9504c16cf2c35",
"CLM:08a48a247c9286d56048a968",
"CLM:230010b55d8fa314c138f186",
"CLM:1706377140c679aaf90692f2"
] | [
"PMCID:PMC10185849",
"PMCID:PMC9098952",
"PMCID:PMC9428701"
] | [
"SPAN:d049af00dce17ed66c08b2fa",
"SPAN:67602ea38a816048a7f33d05",
"SPAN:41a424d8ad80b9cfb678d3be"
] | [
"ASC2:22d664afb02d48023286f260",
"ASC2:3f0f4aa0fdcf3d862a8cde1c"
] | [
"HYP:DCH:f99cfa6ef12d46238d933b4c",
"HYP:DCH:5976eabe15054c9618a56014"
] | {"qa_id":"QA:0ae423913e6a8b4b54fbb6bd","qa_group_id":"QAG:338b1dd00bb29ad3a9b5643f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"5 Compared with standard chemotherapy, PD-1 inhibitor-based therap... |
QA:0b26b19e2e06f0edf1a2c2a1 | QAG:8b861918d1f7bb15dc73b460 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Immunotherapy, with agents such as immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive T-cell therapy, has recently increased hope for improved survival outcomes in patients with esophageal cancer ( 4 – 7 )"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8c3aa91944a30f9fe0a61965","quotes":["Immunotherapy, with agents such as immune checkpoint inhibitors (ICIs), canc... | [
"CLM:8c3aa91944a30f9fe0a61965",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:37f14215d0176fb3050d553e"
] | [] | [] | {"qa_id":"QA:0b26b19e2e06f0edf1a2c2a1","qa_group_id":"QAG:8b861918d1f7bb15dc73b460","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Immunotherapy, with agents such as immune checkpoint inhibitors (I... |
QA:0b26f1060844b4ddcab31b47 | QAG:a8692f23970285d8635331f6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Secondly, in this systematic review and meta-analysis, a total of 1651 ESCC patients from 9 studies received anti-PD1 therapy (tislelizumab, toripalimab, pembrolizumab, camrelizumab, sintilimab, and nivolumab) and only 37 patients from 1 study received anti-PD-L1 thera... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:aabc6746601a9828614ad631","quotes":["Secondly, in this systematic review and meta-analys... | [
"CLM:aabc6746601a9828614ad631",
"CLM:08a48a247c9286d56048a968",
"CLM:4c0180f3f01cfe4f56c46637",
"CLM:e3ac951193a24e565f22521d",
"CLM:b95eb0dee0b66b44200ff790"
] | [
"PMCID:PMC9808083",
"PMCID:PMC8393769",
"PMCID:PMC10022847"
] | [
"SPAN:0f3aaa826acab02f48654fa0",
"SPAN:6cb00b02e2818f82b57926e0",
"SPAN:0ac47b6461f852f718fc1878",
"SPAN:357a066db83a60bea9ed48e5"
] | [
"ASC2:5cbcd9fad85f39973a1c80d6",
"ASC2:b1e2410ebf06ce1f74206866"
] | [
"HYP:DCH:58b2a5a2074f60266f07f4be"
] | {"qa_id":"QA:0b26f1060844b4ddcab31b47","qa_group_id":"QAG:a8692f23970285d8635331f6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Secondly, in this systematic review and meta-analysis, a total of ... |
QA:0b656b757877a3625ae7b030 | QAG:8a0e2a0fe34779d5d22a1ec5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Conclusion Overall, TREM2 + TAM infiltration in ESCC was associated with poor prognosis and may serve as a biomarker for predicting outcomes and immunotherapy modulation in this patient population. modulation; single-cell RNA sequencing Keywords: tumor-associated macro... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:873172d66a6fecd52edd4d08","quotes":["Conclusion Overall, TREM2 + TAM infiltration in ESCC is associated with poor... | [
"CLM:873172d66a6fecd52edd4d08",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:30e1f45d00bfb29c4b388397"
] | [] | [] | {"qa_id":"QA:0b656b757877a3625ae7b030","qa_group_id":"QAG:8a0e2a0fe34779d5d22a1ec5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Conclusion Overall, TREM2 + TAM infiltration in ESCC was associate... |
QA:1026a0a8c6b435c76ac0bd85 | QAG:1ad672e48725f744648a68d3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Consistently, knockdown of OTUD6B using short hairpin RNAs (shRNAs) led to a significant decrease in β ‐TrCP protein but not β ‐TrCP mRNA in KYSE30 and KYSE450 cells, two ESCC cell lines showing high endogenous OTUD6B expression level (Figure 1N,O )"? Return the origin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:790589e45d39ddf4b245c6f8","quotes":["Consistently, knockdown of OTUD6B using short hairpin RNAs (shRNAs) resulted... | [
"CLM:790589e45d39ddf4b245c6f8",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:0ce41e917c382fc651eff9b8"
] | [] | [] | {"qa_id":"QA:1026a0a8c6b435c76ac0bd85","qa_group_id":"QAG:1ad672e48725f744648a68d3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Consistently, knockdown of OTUD6B using short hairpin RNAs (shRNAs... |
QA:118ebb0d424f48ff8ef5cbda | QAG:1ba20d33a44d0551dcca9512 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "It is hypothesized that perioperative immunotherapy could result in prolonged survival based on comparable local tumor control and potential systemic effect for micrometastases"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3e1d30d8ba7744878fed07b0","quotes":["It is hypothesized that perioperative immunotherapy could result in prolonge... | [
"CLM:3e1d30d8ba7744878fed07b0",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC9074348"
] | [
"SPAN:5e7369aed1b8b04a3c9f76ee",
"SPAN:8071432753c9b4b449a6b39c"
] | [] | [] | {"qa_id":"QA:118ebb0d424f48ff8ef5cbda","qa_group_id":"QAG:1ba20d33a44d0551dcca9512","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"It is hypothesized that perioperative immunotherapy could result i... |
QA:14a3b5cd42365c8a41653db1 | QAG:17ac26185708ed0540baa87a | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Patients and Methods Patients with LA-ESCC who received nICT followed by surgery from Jun 2019 to Dec 2021 were enrolled and randomly divided into two sets (7:3)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7717a7eef19904e4924e8aac","quotes":["Patients and Methods Patients with LA-ESCC who received nICT followed by sur... | [
"CLM:7717a7eef19904e4924e8aac",
"CLM:08adec9d2dfaf31bc5d24f84"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:e122466691681ae1b0194be5"
] | [] | [] | {"qa_id":"QA:14a3b5cd42365c8a41653db1","qa_group_id":"QAG:17ac26185708ed0540baa87a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Patients and Methods Patients with LA-ESCC who received nICT follo... |
QA:1585e39fb9e189efd6fcd05a | QAG:77d8da0467fd0d85f296e63e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Methods The enrolled patients with resectable (clinical stage II to IVA) ESCC received neoadjuvant sintilimab injection (200 mg/time, day 1), paclitaxel liposomes (135 mg/m 2 , day 1), and carboplatin (area under curve of 5 mg/mL/min, day 1) every 21 days for 2 cycles,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba4f6489aaeb1263201db7e0","quotes":["Methods The enrolled patients with resectable (clin... | [
"CLM:ba4f6489aaeb1263201db7e0",
"CLM:0991831bbf7006fe9faffdbf",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9606329",
"PMCID:PMC8557514"
] | [
"SPAN:d8fb2eb9246a7d330a888edb",
"SPAN:d248e03a9c0effcd8331ba03"
] | [
"ASC2:d6a1d7a195e23269d8bec94c"
] | [
"HYP:DCH:141fdf08a4d347e880b743e9"
] | {"qa_id":"QA:1585e39fb9e189efd6fcd05a","qa_group_id":"QAG:77d8da0467fd0d85f296e63e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Methods The enrolled patients with resectable (clinical stage II t... |
QA:15a9d6be02f7cca46873340d | QAG:b4d28f3e64e28adce6638cba | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "To date, there have been no RCTs that directly compare the therapeutic efficacy of different chemotherapy regimens in advanced or metastatic ESCC patients who received first-line chemo-immunotherapy"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fba223e78c6967977770b439","quotes":["To date, there have been no RCTs that directly compare the therapeutic effic... | [
"CLM:fba223e78c6967977770b439",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9808083"
] | [
"SPAN:7c45b1369619ff5884fa6310"
] | [] | [] | {"qa_id":"QA:15a9d6be02f7cca46873340d","qa_group_id":"QAG:b4d28f3e64e28adce6638cba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"To date, there have been no RCTs that directly compare the therape... |
QA:15e63ee6fdc33fdf7f5f1bad | QAG:7e5704bc5bccecd897d7aa8e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 1970 trial participants from the five RCTs were included in this study, of which 987 received anti-PD-1 agent as a monotherapy for ESCC, while the other 983 received chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2f26959a7a6070c8781e256c","quotes":["A total of 1970 trial participants from the five RCTs were included in this ... | [
"CLM:2f26959a7a6070c8781e256c",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8579527"
] | [
"SPAN:7dc09a9c47ed3fdf68375e12"
] | [] | [] | {"qa_id":"QA:15e63ee6fdc33fdf7f5f1bad","qa_group_id":"QAG:7e5704bc5bccecd897d7aa8e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 1970 trial participants from the five RCTs were include... |
QA:16208b88079e6bb4c31dd2a8 | QAG:45f94c74aa0ef5dd37bd32a4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Recently, a study including 64 LA-ESCC patients who received nICT analyzed the associations between several indicators (NLR, PLR, LMR and SII) and pCR"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a81927d6f0dbe92f23d5f288","quotes":["Recently, a study including 64 LA-ESCC patients who received nICT analyzed t... | [
"CLM:a81927d6f0dbe92f23d5f288",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:301da096c374f2cf46156e05"
] | [] | [] | {"qa_id":"QA:16208b88079e6bb4c31dd2a8","qa_group_id":"QAG:45f94c74aa0ef5dd37bd32a4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Recently, a study including 64 LA-ESCC patients who received nICT ... |
QA:1705ab815e36fd165f8d6106 | QAG:71003c5c6bb5b1ca2cc5b256 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "CONTEXT Key Objective This study aims to evaluate whether patients with advanced esophageal squamous cell carcinoma (ESCC) with low programmed cell death ligand 1 (PD-L1) expression would benefit from programmed death-1 (PD-1) antibody plus chemotherapy over chemothera... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e3ac951193a24e565f22521d","quotes":["CONTEXT Key Objective This study aimed to determine... | [
"CLM:e3ac951193a24e565f22521d",
"CLM:23c554d40e73d21b46b8fb97",
"CLM:b95eb0dee0b66b44200ff790"
] | [
"PMCID:PMC10022847",
"PMCID:PMC9808083"
] | [
"SPAN:357a066db83a60bea9ed48e5",
"SPAN:0ac47b6461f852f718fc1878"
] | [
"ASC2:b1e2410ebf06ce1f74206866"
] | [
"HYP:DCH:17a25e9a854547e3642190a1"
] | {"qa_id":"QA:1705ab815e36fd165f8d6106","qa_group_id":"QAG:71003c5c6bb5b1ca2cc5b256","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"CONTEXT Key Objective This study aims to evaluate whether patients... |
QA:172358308c0c7292d85b6dc4 | QAG:3f96a9f7b82fbc59cc5b282d | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Moreover, low OTUD6B expression was correlated with decreased β ‐TrCP and increased SNAIL protein level in ESCC tissues and predicts a poor prognosis in ESCC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c37aaf1900391c6784633d34","quotes":["Moreover, low OTUD6B expression is significantly correlated with decreased β... | [
"CLM:c37aaf1900391c6784633d34",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:b979c28084511af877826a54"
] | [] | [] | {"qa_id":"QA:172358308c0c7292d85b6dc4","qa_group_id":"QAG:3f96a9f7b82fbc59cc5b282d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Moreover, low OTUD6B expression was correlated with decreased β ‐T... |
QA:17ee084ef1c20343d96384e3 | QAG:9779c0b5b39640e284216f87 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In this study, we identified that NLR at 6 weeks after anti-PD-1 treatment was able to predict the response to anti-PD-1 antibody in patients with ESCC, and a decrease in NLR after treatment predicted a better treatment response to anti-PD-1 therapy"? Return the origin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:93429e243007d4c2782f0067","quotes":["In this study, we identified that NLR at 6 weeks after anti-PD-1 treatment w... | [
"CLM:93429e243007d4c2782f0067",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8262036"
] | [
"SPAN:41e677c153dee39de170a2f5"
] | [] | [] | {"qa_id":"QA:17ee084ef1c20343d96384e3","qa_group_id":"QAG:9779c0b5b39640e284216f87","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In this study, we identified that NLR at 6 weeks after anti-PD-1 t... |
QA:18ebe49a904d45d3593cb4cf | QAG:266388102b8fbd0b98ff9a07 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Compared with chemotherapy, PD-1 inhibitor-based therapy prolonged OS as a first-line treatment (HR: 0.69; 95% CI: 0.64-0.74) or second-line treatment (HR: 0.74; 95% CI: 0.66-0.82) in patients with ESCC ( Figure 2A )"? Return the original wording with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ad79801a0e4ef7af1aada49a","quotes":["Compared with chemotherapy, PD-1 inhibitor-based therapy significantly prolo... | [
"CLM:ad79801a0e4ef7af1aada49a",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10185849"
] | [
"SPAN:7e0b74a6ee4277537e5d4cc2"
] | [] | [] | {"qa_id":"QA:18ebe49a904d45d3593cb4cf","qa_group_id":"QAG:266388102b8fbd0b98ff9a07","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Compared with chemotherapy, PD-1 inhibitor-based therapy prolonged... |
QA:1a7dd98728d3dc8aebedcb44 | QAG:0288e063f3ee2b37fc036152 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "(III) had previously received surgical or endoscopic interventional treatment for ESCC; (IV) had previously received radiotherapy or systemic anti-cancer therapy; (V) suffered from active tuberculosis; (VI) had an esophageal fistula before treatment; and/or (VII) had d... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:63ff413d7d8ae1681fab95d2","quotes":["Patients were excluded if they met any of the following criteria: (I) had no... | [
"CLM:63ff413d7d8ae1681fab95d2",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC9577786"
] | [
"SPAN:5b2448bc02f2ad68e37c2102"
] | [] | [] | {"qa_id":"QA:1a7dd98728d3dc8aebedcb44","qa_group_id":"QAG:0288e063f3ee2b37fc036152","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"(III) had previously received surgical or endoscopic interventiona... |
QA:1b4ab787388e44a3acf50ca0 | QAG:d985fc3eb30edfb1ee2daee4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "9%) patients achieved CR and PR, respectively, with no grade 3/4 AEs ( 62 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e62711588c137a040af8b3b9","quotes":["3.2.1. In a clinical study of radiotherapy combined with anti-PD-1 Camrelizu... | [
"CLM:e62711588c137a040af8b3b9",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:bc579813eb73dd577cba7fe0"
] | [] | [] | {"qa_id":"QA:1b4ab787388e44a3acf50ca0","qa_group_id":"QAG:d985fc3eb30edfb1ee2daee4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"9%) patients achieved CR and PR, respectively, with no grade 3/4 A... |
QA:1cd04d376483a7808d5b9925 | QAG:f66382ebdf0ab0c242bba1a5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "These results elicited that the close interaction between tumor cells and APCs with different PD-L1 expression led to divergent outcome of chemoradiotherapy combined with PD-1 blockade in ESCC"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f4a72531f8c02a032f05a494","quotes":["These results elicited that the close interaction between tumor cells and AP... | [
"CLM:f4a72531f8c02a032f05a494",
"CLM:0991831bbf7006fe9faffdbf"
] | [
"PMCID:PMC8761740"
] | [
"SPAN:7979969190336540fb3306f2"
] | [] | [] | {"qa_id":"QA:1cd04d376483a7808d5b9925","qa_group_id":"QAG:f66382ebdf0ab0c242bba1a5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"These results elicited that the close interaction between tumor ce... |
QA:1f233c7dbaf8540200f1ee52 | QAG:347f46e505d5805a4cab657e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In this study, we unveiled that the baseline NLR and HLA‐I genotyping was associated with clinical outcomes of the advanced ESCC patients receiving camrelizumab monotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prove... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fbb58d251c8bdfd098c8f370","quotes":["In this study, we unveiled that the baseline NLR and HLA‐I genotyping were a... | [
"CLM:fbb58d251c8bdfd098c8f370",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9161342"
] | [
"SPAN:16e04d9192c2838dc7cfae47"
] | [] | [] | {"qa_id":"QA:1f233c7dbaf8540200f1ee52","qa_group_id":"QAG:347f46e505d5805a4cab657e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In this study, we unveiled that the baseline NLR and HLA‐I genotyp... |
QA:1ff10d70824bb03cdcf40f97 | QAG:53dec2fcb54a38c33d63b8d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Importantly, a lower β ‐TrCP protein level was associated with poor overall survival in ESCC patients (Figure 1D,E ), suggesting its potential role as a tumor suppressor in this cancer type"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:858c923cd38f3612bb51fc2e","quotes":["Importantly, a lower β ‐TrCP protein level was associated with poor overall ... | [
"CLM:858c923cd38f3612bb51fc2e",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10238178"
] | [
"SPAN:b670cbdd570ff5860c99abb3"
] | [] | [] | {"qa_id":"QA:1ff10d70824bb03cdcf40f97","qa_group_id":"QAG:53dec2fcb54a38c33d63b8d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Importantly, a lower β ‐TrCP protein level was associated with poo... |
QA:20d13d9bfa87f7724abeba03 | QAG:61e6f0ec9a8e20e0eaf409b9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "For locally advanced resectable ESCC, adding immunotherapy to standard care of the neoadjuvant chemoradiotherapy followed by surgery has not significantly increased the pCR rate but has increased toxicity to some extent"? Return the original wording with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a606d86c366a919f0fe41684","quotes":["For locally advanced resectable ESCC, adding immunotherapy to standard care ... | [
"CLM:a606d86c366a919f0fe41684",
"CLM:2a0dc33e26036765ea69bb10"
] | [
"PMCID:PMC10261849"
] | [
"SPAN:5296239b0e6a815d33da6e01"
] | [] | [] | {"qa_id":"QA:20d13d9bfa87f7724abeba03","qa_group_id":"QAG:61e6f0ec9a8e20e0eaf409b9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"For locally advanced resectable ESCC, adding immunotherapy to stan... |
QA:21ef516fc89f7c745b063781 | QAG:431b3f4a403776ff2beff0ce | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A total of 285 (training set = 200 and validation set = 85) patients with LA-ESCC treated with nICT followed by radical resection were included in the current study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e7dfac155e02a385afdd8a7d","quotes":["A total of 285 (training set = 200 and validation set = 85) patients with LA... | [
"CLM:e7dfac155e02a385afdd8a7d",
"CLM:0313c682e9e59efb742366b7"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:0276c444eafd123ca223ff83"
] | [] | [] | {"qa_id":"QA:21ef516fc89f7c745b063781","qa_group_id":"QAG:431b3f4a403776ff2beff0ce","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A total of 285 (training set = 200 and validation set = 85) patien... |
QA:2279ebc02bc492537d51ccc8 | QAG:d99c972e710d59d13c46eaec | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "A phase II study (NICE) , conducted by our group achieved a 39.2% pCR rate and acceptable toxicity in locally advanced ESCC after preoperative camrelizumab plus weekly chemotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrat... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:59be64c05060f725461e5885","quotes":["A phase II study (NICE) [ 11 ], conducted by our group, achieved a 39.2% pCR... | [
"CLM:59be64c05060f725461e5885",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC9074348"
] | [
"SPAN:0b948bb7a7d19e2e02c29c07"
] | [] | [] | {"qa_id":"QA:2279ebc02bc492537d51ccc8","qa_group_id":"QAG:d99c972e710d59d13c46eaec","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"A phase II study (NICE) , conducted by our group achieved a 39.2% ... |
QA:26669c342ec616f5c2f672d7 | QAG:cfb2f4e306fdce1a6cee07e8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In our study, CD73 silencing decreased tumor cell migration, invasion, and EMT process in ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c613a6ea3d7fc2853fc10b16","quotes":["In our study, CD73 silencing decreased tumor cell migration, invasion, and E... | [
"CLM:c613a6ea3d7fc2853fc10b16",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:ad580fed24b78565eabb543f"
] | [] | [] | {"qa_id":"QA:26669c342ec616f5c2f672d7","qa_group_id":"QAG:cfb2f4e306fdce1a6cee07e8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In our study, CD73 silencing decreased tumor cell migration, invas... |
QA:28956a0a17d3a9fe27f791b5 | QAG:0facf71c0c396a40f3f1d27b | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "(2) Patients received chemotherapy combined with immunotherapy based on PD‐1/PD‐L1 or chemotherapy alone; (3) Advanced ESCC was diagnosed; (4) The outcome of interest is efficacy and toxicity; and (5) Studies published in English"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:82519f5fd1ceaae32bee2f93","quotes":["2.2 Study inclusion criteria: (1) Randomized controlled trial (RCT); (2) Pat... | [
"CLM:82519f5fd1ceaae32bee2f93",
"CLM:23c554d40e73d21b46b8fb97"
] | [
"PMCID:PMC10363809"
] | [
"SPAN:a9be6b1a3685ab954205954f"
] | [] | [] | {"qa_id":"QA:28956a0a17d3a9fe27f791b5","qa_group_id":"QAG:0facf71c0c396a40f3f1d27b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"(2) Patients received chemotherapy combined with immunotherapy bas... |
QA:29d68f764e817c49442ee994 | QAG:326d511886a81700546f1a28 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Using least absolute shrinkage and selection operator (LASSO) logistic regression analysis, the IINS was constructed in LA-ESCC patients received nICT to predict pCR"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cef4eeda07b2561909282673","quotes":["Using least absolute shrinkage and selection operator (LASSO) logistic regre... | [
"CLM:cef4eeda07b2561909282673",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:dd37b834f4f641c25ab961bb"
] | [] | [] | {"qa_id":"QA:29d68f764e817c49442ee994","qa_group_id":"QAG:326d511886a81700546f1a28","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Using least absolute shrinkage and selection operator (LASSO) logi... |
QA:2a2a18f9b12a825a94adf13a | QAG:176ecfddd46f2503158e7fd4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "The results showed that immune checkpoint inhibitor treatment as second- or later-line treatment was associated with an increased risk of the objective response rate (relative risk: 1.82, 95% confidence interval: 0.82–4.04; P=0.002) and median overall survival (hazard ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5c64554915a77f8fe790d8fc","quotes":["The results showed that immune checkpoint inhibitor treatment as second- or ... | [
"CLM:5c64554915a77f8fe790d8fc",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8724211"
] | [
"SPAN:54135a55bcccb0f9762bf659"
] | [] | [] | {"qa_id":"QA:2a2a18f9b12a825a94adf13a","qa_group_id":"QAG:176ecfddd46f2503158e7fd4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"The results showed that immune checkpoint inhibitor treatment as s... |
QA:2ab260cad00cc49dd326cbfa | QAG:72419c1030bca785c0b87245 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Moreover, based on the expression data of the 80 TCGA patients with ESCC, TIDE predicted that the High abundance group was more resistant to immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:84ae136739816619c565a289","quotes":["Moreover, based on the expression data of the 80 TCGA patients with ESCC, TI... | [
"CLM:84ae136739816619c565a289",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC10175681"
] | [
"SPAN:df0eec89f789093befb6d705"
] | [] | [] | {"qa_id":"QA:2ab260cad00cc49dd326cbfa","qa_group_id":"QAG:72419c1030bca785c0b87245","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Moreover, based on the expression data of the 80 TCGA patients wit... |
QA:2c717046fe6769138c06a7d3 | QAG:c23bfd3018a7498f6c84c856 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Immunotherapy improved the long-time survival of advanced ESCC in the ATTRACTION and KEYNOTE studies"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:54ae4e2a9ff74efa6426022d","quotes":["Immunotherapy significantly improved the long-time survival of advanced ESCC... | [
"CLM:54ae4e2a9ff74efa6426022d",
"CLM:08a48a247c9286d56048a968"
] | [
"PMCID:PMC9271687"
] | [
"SPAN:1a49ce298583a4f47685b266"
] | [] | [] | {"qa_id":"QA:2c717046fe6769138c06a7d3","qa_group_id":"QAG:c23bfd3018a7498f6c84c856","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Immunotherapy improved the long-time survival of advanced ESCC in ... |
QA:2c7c66ee9e1da4505d954856 | QAG:1fd46970744e76c61ee17d4e | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "In a phase III study of advanced esophageal cancer, KEYNOTE-181, patients with CPS ≥ 10 who received pembrolizumab had a better response rate and OS compared to those who received chemotherapy"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d07d0e19b0b9667138dfb755","quotes":["In a phase III study of advanced esophageal cancer, KEYNOTE-181, patients wi... | [
"CLM:d07d0e19b0b9667138dfb755",
"CLM:02001ad96144c794bcc3e9a5"
] | [
"PMCID:PMC8393769"
] | [
"SPAN:a3b22a554f92238d551cc368"
] | [] | [] | {"qa_id":"QA:2c7c66ee9e1da4505d954856","qa_group_id":"QAG:1fd46970744e76c61ee17d4e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"In a phase III study of advanced esophageal cancer, KEYNOTE-181, p... |
QA:2f6116c444fdc127f0e8d784 | QAG:8cb77c098a489f369cdb83e9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "These results suggested that the PD-L1 - DCs and macrophages in the tumor compartments promoted antitumor efficacy of chemoradiotherapy combined with PD-1 blockade in ESCC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated proven... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d7a90a3a5e42ef7e4a92fb98","quotes":["These results suggested that the PD-L1 - DCs and ma... | [
"CLM:d7a90a3a5e42ef7e4a92fb98",
"CLM:0991831bbf7006fe9faffdbf",
"CLM:30381d7ec9b808796a0b1d61"
] | [
"PMCID:PMC8761740",
"PMCID:PMC8579527"
] | [
"SPAN:20f41b3780381061c5907778",
"SPAN:b6fcca4729328b49ea369c2b"
] | [
"ASC2:099c7f88ac273ef4225c1fd7"
] | [] | {"qa_id":"QA:2f6116c444fdc127f0e8d784","qa_group_id":"QAG:8cb77c098a489f369cdb83e9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"These results suggested that the PD-L1 - DCs and macrophages in th... |
QA:300d07d5ae3bd55608ca0628 | QAG:5cc7cfe98f080131f2c4dd59 | provenance_qa | exact_evidence_retrieval | provenance_qa | G023 | en | train | Which exact source passage supports the statement "Stage IVB ESCC patients who had failed first-line immunochemotherapy received primary tumor radiotherapy (40GY/20F)/metastatic lesions radiotherapy (30GY/10F) combined with Camrelizumab and irinotecan achieved an ORR of 40.8%, a DCR of 75.5%, with median PFS and OS of ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:279ac1ac7468c5fbc828a8ce","quotes":["Stage IVB ESCC patients wh... | [
"CLM:279ac1ac7468c5fbc828a8ce",
"CLM:08a48a247c9286d56048a968",
"CLM:1f6c0c04f1092da2733c0b22",
"CLM:4a3471322cb61914835a391c"
] | [
"PMCID:PMC10261849",
"PMCID:PMC9428701",
"PMCID:PMC8579527"
] | [
"SPAN:ba9785b6444fe128a8f3bf11",
"SPAN:8d6e0f43e4e8e7203c3c5b17",
"SPAN:2b581b6dc16736c1768d9339"
] | [
"ASC2:3e8e1c1606f5c7347eafe10d",
"ASC2:e40fe99f05a8670b4a172f37"
] | [
"HYP:DCH:938b873d99172f2f7ff258cf",
"HYP:DCH:094ced7236e1463a148199f0"
] | {"qa_id":"QA:300d07d5ae3bd55608ca0628","qa_group_id":"QAG:5cc7cfe98f080131f2c4dd59","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G023","question":"Which exact source passage supports the statement \"Stage IVB ESCC patients who had failed first-line immunochemothera... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.